Our thoughts on the news
Peptide regulation is moving, and most of what gets written about it blurs distinctions that matter. We report what changed, say plainly what didn’t, and link the primary document every time.
- How to read a certificate of analysis, using one of oursA certificate with one number on it is decoration. A real one names the lot, the method, the limits, and the results, and lets you pull the same document from the lab yourself.Evergreen. The example is a real certificate on a real lot.
- Five minutes at a time: what our founder told the FDAOur founder spoke five times at the FDA's Pharmacy Compounding Advisory Committee over two days in July 2026. Every word is published here, with the webcast timecode for each statement.The statements are public record. As of September 18, 2026, the FDA hadn't posted an official transcript.
- The committee voted. That's not the same as access.The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides on July 23–24, 2026 and recommended six. A recommendation is one step in a long process. Here's what actually changed, and what didn't.Recommended by the advisory committee. Still not compoundable; the FDA hasn't acted on the recommendation.
We go to the primary document instead of someone’s summary of it. We never call a committee recommendation an approval. We keep compounding, outsourcing, approved drugs, and research use as the four separate lanes they are. When we can’t verify something, we say so instead of rounding it up into a claim. This is reporting and commentary, and it isn’t legal advice.